How to Compare Funds That Own the Same Stock Without Assuming the Same Thesis
A practical guide to comparing two or more funds that hold the same company, without treating shared ownership as proof that they are making the same bet.
Two funds can own the same stock and still be making completely different bets. That sounds obvious, but it is one of the most common mistakes in 13F analysis. Investors see overlapping ownership in names like Nvidia, Microsoft or Amazon and assume the overlap itself is the insight. Usually it is not. The real insight is in how each manager owns the stock, where it sits in the book and what changed around it.
This matters because institutional ownership is full of false equivalence. A global index-heavy platform, a growth manager and a quant shop can all hold the same company for different reasons. If you skip that context, you start telling yourself stories the filing never said. Shared ownership is a clue. It is not the thesis.
Start With Position Size
The fastest way to separate similar-looking holders is to compare the stock's weight in each portfolio. A 6% position means something very different from a 0.40% position. If Capital World Investors has a stock near the top of the book while a much larger platform carries the same name as a small residual weight, the overlap is real but the conviction is not equal. One manager may be leaning into a thesis. The other may simply be unable to avoid the stock because of benchmark gravity.
This is why weight almost always matters more than raw dollars. A trillion-dollar platform can own more of a company in absolute terms than a specialist fund and still care less about it relative to the rest of the portfolio. Dollar value tells you scale. Weight tells you importance.
Then Ask What Role the Stock Plays
A stock can serve as a core growth compounder, a tactical trade, a sector placeholder or an index-like necessity. Those roles are not interchangeable. If two managers both own Broadcom, for example, one may be using it as a central AI infrastructure holding while another simply needs semiconductor exposure inside a broader market sleeve. Looking only at the overlap hides that difference.
The easiest way to see role is to compare the stock with the rest of each portfolio. What sits above it? What sits beside it? If a manager holds Nvidia, Microsoft and Broadcom near the top, the thesis may be concentrated around AI infrastructure and platform leverage. If the same stock is surrounded by broad ETFs, banks and defensive sectors, the portfolio may be telling a more diversified or benchmark-aware story.
Turnover Changes the Interpretation
Next, compare what changed. Did both managers increase the position? Did one hold it flat while the other added aggressively? Did the stock rise in ranking because of price appreciation rather than because the fund bought more shares? These questions matter more than the existence of the position itself.
This is where quarter-over-quarter reading becomes essential. A stock that remains a top holding at UBS Group AG after broad-index cuts may mean something different from the same stock sitting unchanged inside Rhumbline Advisers. One manager may be making a subtle preference shift. The other may be reflecting broad market structure. Overlap without turnover context turns those two cases into one false story.
Manager Type Matters More Than People Admit
Before comparing holders, classify them. Are you looking at a passive giant, a wealth platform, a quant allocator, an insurance account, a sovereign entity or an active stock picker? That classification should come before the stock-level analysis, not after it. A stock appearing in Vanguard, BlackRock and State Street tells you far less about active conviction than the same stock appearing as a top weight in several concentrated active managers.
That is why “smart money overlap” needs to be handled carefully. Some overlap is genuinely informative. Some is just the market owning itself through giant distribution systems. The harder you separate active thesis from structural ownership, the more useful the comparison becomes.
Use the Surrounding Portfolio as Evidence
If two managers own the same stock, compare their top ten. Is the rest of the portfolio aligned with the same idea, or does the shared position sit inside entirely different contexts? A manager that pairs Netflix with software, semiconductors and cloud infrastructure may be expressing one kind of growth view. Another that pairs it with consumer defensives, banks and broad ETFs may simply be keeping a high-quality consumer internet name inside a more balanced portfolio.
This is often the hidden edge in 13F analysis. The stock overlap gets the attention, but the surrounding holdings explain what the overlap really means. Once you compare the company with its neighbors, you stop treating every shared position as a shared thesis.
The Practical Rule
When two funds own the same stock, compare four things in order: weight, ranking, turnover and portfolio neighbors. Only after that should you ask whether the thesis looks similar. In many cases the answer will be no, and that is exactly the point. Institutional overlap is common. True thesis overlap is rarer.
That is why good comparison work feels slower than people expect. You are not just checking whether both portfolios contain Microsoft or Nvidia. You are asking what job the stock is doing in each book. Once you make that shift, overlapping ownership becomes much more informative and much less misleading.
Related Research
Explore all researchKEYBANK NATIONAL ASSOCIATION/OH reported 27.38B in 2026Q1 13F assets. The filing is most useful as a holder-depth and concentration map, not a raw clone list.
Retirement Systems of Alabama reported 29.98B in 2026Q1 13F assets. The filing is most useful as a holder-depth and concentration map, not a raw clone list.
WEALTH ENHANCEMENT ADVISORY SERVICES, LLC reported 49.10B in 2026Q1 13F assets. The filing is most useful as a holder-depth and concentration map, not a raw clone list.
Wasatch Advisors' 2026Q1 13F showed a $15.06B reported book led by HealthEquity, Ensign, Medpace and a set of small and mid-cap growth names.
Pzena Investment Management's 2026Q1 13F looked nothing like a mega-cap AI basket, with Magna, Cognizant, Tyson, Baxter and Bristol Myers among the top holdings.